A Non-randomized, Open-label, Multicenter Study to Evaluate the Safety and Tolerability of 10% Aminolevulinic Acid Gel in the Expanded Field-directed Treatment of Actinic Keratosis on the Face and Scalp with Red Light Photodynamic Therapy
Authors:
- 1 April 2025
- journal article
- Vol. 18 (4) , 44-50
Abstract
Dermatologists regularly encounter patients having expanded fields with numerous actinic keratosis (AK) lesions on the face and scalp. Field-directed red light photodynamic therapy (PDT) is a well-established treatment, yet published data on the safety of PDT on large areas is scarce. We aimed to evaluate the safety and tolerability of red light PDT in treating expanded AK fields on the face and scalp. This was a non-randomized, open-label, multicenter study. After lesion preparation, 6g of 10% aminolevulinic acid (ALA) gel were applied to the treatment field (60 cm2) and incubated for three hours under a light-blocking, occlusive dressing before 10-minute illumination with a red light lamp (~635nm, 37 J/cm2). Safety and tolerability were assessed throughout the study. All participants (n=100) had adverse reactions. No previously unknown effects, serious adverse events, or deaths were reported. The most frequent application site reactions were pain/burning (96.0%), exfoliation (87.0%), and erythema (86.0%). Most treatment-emergent adverse events were of mild to moderate severity and lasted slightly longer compared to those experienced after treatment of smaller areas. The mean maximum pain during PDT was 7.4±2.1 on an 11-point numeric rating scale. A transient increase in blood pressure on the day that PDT was performed was not clinically significant. Although the allowed use of pain-reducing measures might have influenced evaluation of pain, it reflects how the procedure is managed in current practice. PDT with 10% ALA gel and red light illumination on an expanded treatment field was generally well tolerated.Keywords
This publication has 47 references indexed in Scilit:
- Factors influencing pain intensity during topical photodynamic therapy of complete cosmetic units for actinic keratosesJournal of the American Academy of Dermatology, 2010
- Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a prospective, randomized, double-blind, placebo-controlled phase III studyBritish Journal of Dermatology, 2010
- Pain associated with aminolevulinic acid-photodynamic therapy of skin diseaseJournal of the American Academy of Dermatology, 2009
- Actinic keratosesCancer, 2009
- Predictors of Significant Short-Term Increases in Blood Pressure in a Community-Based PopulationThe American Journal of Medicine, 2007
- Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: An international consensusJournal of the American Academy of Dermatology, 2007
- Frequency and Cost of Actinic Keratosis TreatmentDermatologic Surgery, 2006
- Actinic keratoses: sequelae and treatments. Recommendations from a consensus panel.2006
- A Trial of Short Incubation, Broad-Area Photodynamic Therapy for Facial Actinic Keratoses and Diffuse PhotodamageArchives of Dermatology, 2004
- A double-blind, vehicle-controlled study evaluating masoprocol cream in the treatment of actinic keratoses on the head and neckJournal of the American Academy of Dermatology, 1991